Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.

The text reports on the results from Arm A of the Phase 1/2 DREAMM-6 trial, focusing on the combination of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma. The study showed no dose-limiting toxicities and no new safety signals across cohorts, with adverse events consistent with individual agent safety profiles. Ocular events, particularly keratopathy, were the most common Grade 3/4 adverse events, and the overall safety profile was manageable. Efficacy outcomes, such as overall response rate and progression-free survival, were generally similar across cohorts, indicating clinically meaningful anti-myeloma activity. [Extracted from the article]